Your browser doesn't support javascript.
A Cost-Benefit Analysis of COVID-19 Vaccination in Catalonia.
López, Francesc; Català, Martí; Prats, Clara; Estrada, Oriol; Oliva, Irene; Prat, Núria; Isnard, Mar; Vallès, Roser; Vilar, Marc; Clotet, Bonaventura; Argimon, Josep Maria; Aran, Anna; Ara, Jordi.
  • López F; Directorate for Innovation and Interdisciplinary Cooperation, North Metropolitan Territorial Authority, Catalan Institute of Health, 08006 Barcelona, Spain.
  • Català M; Centre for Research in Health and Economics, Pompeu Fabra University, 08002 Barcelona, Spain.
  • Prats C; Fight AIDS and Infectious Diseases Foundation, 08916 Barcelona, Spain.
  • Estrada O; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, 08916 Barcelona, Spain.
  • Oliva I; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, 08916 Barcelona, Spain.
  • Prat N; BIOCOM-SC, Physics Department, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain.
  • Isnard M; Directorate for Innovation and Interdisciplinary Cooperation, North Metropolitan Territorial Authority, Catalan Institute of Health, 08006 Barcelona, Spain.
  • Vallès R; Directorate for Innovation and Interdisciplinary Cooperation, North Metropolitan Territorial Authority, Catalan Institute of Health, 08006 Barcelona, Spain.
  • Vilar M; Centre for Research in Health and Economics, Pompeu Fabra University, 08002 Barcelona, Spain.
  • Clotet B; North Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.
  • Argimon JM; North Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.
  • Aran A; North Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.
  • Ara J; North Metropolitan Primary Care Directorate, Catalan Institute of Health, 08006 Barcelona, Spain.
Vaccines (Basel) ; 10(1)2021 Dec 31.
Статья в английский | MEDLINE | ID: covidwho-1614022
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
(1)

Background:

In epidemiological terms, it has been possible to calculate the savings in health resources and the reduction in the health effects of COVID vaccines. Conducting an economic evaluation, some studies have estimated its cost-effectiveness; the vaccination shows highly favorable results, cost-saving in some cases. (2)

Methods:

Cost-benefit analysis of the vaccination campaign in the North Metropolitan Health Region (Catalonia). An epidemiological model based on observational data and before and after comparison is used. The information on the doses used and the assigned resources (conventional hospital beds, ICU, number of tests) was extracted from administrative data from the largest primary care provider in the region (Catalan Institute of Health). A distinction was made between the social perspective and the health system. (3)

Results:

the costs of vaccination are estimated at 137 million euros (€48.05/dose administered). This figure is significantly lower than the positive impacts of the vaccination campaign, which are estimated at 470 million euros (€164/dose administered). Of these, 18% corresponds to the reduction in ICU discharges, 16% to the reduction in conventional hospital discharges, 5% to the reduction in PCR tests and 1% to the reduction in RAT tests. The monetization of deaths and cases that avoid sequelae account for 53% and 5% of total savings, respectively. The benefit/cost ratio is estimated at 3.4 from a social perspective and 1.4 from a health system perspective. The social benefits of vaccination are estimated at €116.67 per vaccine dose (€19.93 from the perspective of the health system). (4)

Conclusions:

The mass vaccination campaign against COVID is cost-saving. From a social perspective, most of these savings come from the monetization of the reduction in mortality and cases with sequelae, although the intervention is equally widely cost-effective from the health system perspective thanks to the reduction in the use of resources. It is concluded that, from an economic perspective, the vaccination campaign has high social returns.
ключевые слова

Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Тип исследования: Экспериментальные исследования / Наблюдательное исследование / Прогностическое исследование Темы: Длинный Ковид / Вакцина Язык: английский Год: 2021 Тип: Статья Аффилированная страна: Vaccines10010059

Документы, близкие по теме

MEDLINE

...
LILACS

LIS


Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Тип исследования: Экспериментальные исследования / Наблюдательное исследование / Прогностическое исследование Темы: Длинный Ковид / Вакцина Язык: английский Год: 2021 Тип: Статья Аффилированная страна: Vaccines10010059